A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.

Pfizer 's newest bet on obesity is already showing promise.

The company last week said it would buy weight loss drugmaker Metsera in an up to $7.3 billion deal , including future payments, that is expected to close at the end of the year. Just a week later, Metsera released data from mid-stage trials on its lead obesity drug candidate that will allow the company to start phase three studies on the treatment later this year.

Metsera, founded in 2022, brings a pipeline of both oral and injectable treatments with different targets. The company picked up those drugs through its own licensi

See Full Page